SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 25th, 2016 • Sparkle Byte LTD • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is made as of September 20, 2015, between CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), He Xie Ai Qi Investment Management (Beijing) Co., Ltd. (和谐爱奇投资管理（北京）有限公司), a company formed under the laws of the People’s Republic of China (“HXAQ”) and any Person that delivers any portion of the Subscription Amount pursuant to Section 2.02(b) of this Agreement (such Persons, together with HXAQ, jointly and severally, and including their successors and assigns, the “Purchaser”).
JOINT FILING AGREEMENT February 20, 2024Joint Filing Agreement • February 20th, 2024 • Sparkle Byte LTD • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing, on behalf of each of them, of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.01 per share of CASI Pharmaceuticals, Inc., a Delaware corporation; and (ii) that this agreement be included as Exhibit 99.4 to such joint filing. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.
Supplemental AgreementSupplemental Agreement • June 30th, 2016 • Sparkle Byte LTD • Biological products, (no disgnostic substances)
This supplemental agreement (this “Agreement”) is entered into as of June 22, 2016 by and among CASI Pharmaceuticals, Inc. (the “Company”), He Xie Ai Qi Investment Management (Beijing) Co., Ltd. (和谐爱奇投资管理（北京）有限公司) (“HXAQ”), Tianjin Jingran Management Center (Limited Partnership) (“Tianjin Jingran”), a limited partnership controlled by HXAQ, and Sparkle Byte Limited (“Sparkle Byte”), an indirect wholly-owned subsidiary of Tianjin Jingran. Capitalized terms used herein but not otherwise defined herein shall have the respective meanings given to such terms in the Purchase Agreement (as defined below).
JOINT FILING AGREEMENT January 25, 2016Joint Filing Agreement • January 25th, 2016 • Sparkle Byte LTD • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing, on behalf of each of them, of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.01 per share of CASI Pharmaceuticals, Inc., a Delaware corporation; and (ii) that this agreement be included as Exhibit 99.1 to such joint filing. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.
